A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT01521923. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 \[NCT01519791\]. Subjects entering this study RA0055 Period 2 achieved sustained Low Disease Activity at Week 52 in study RA0055 Period 1.
Study identification
- NCT ID
- NCT01521923
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 359 participants
Conditions and interventions
Conditions
Interventions
- Certolizumab Pegol + Methotrexate (MTX) Biological
- Placebo + Methotrexate (MTX) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2012 (Type not available)
- Primary completion
- Jul 2015 (Actual)
- Completion
- Sep 2015 (Actual)
- Last update posted
- Aug 25, 2026
2012 – 2015
United States locations
- U.S. sites
- 70
- U.S. states
- 31
- U.S. cities
- 66
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 209 | Birmingham | Alabama | — | — |
| 170 | Huntsville | Alabama | — | — |
| 180 | Mobile | Alabama | — | — |
| 247 | Glendale | Arizona | — | — |
| 165 | Paradise Valley | Arizona | — | — |
| 234 | Paradise Valley | Arizona | — | — |
| 243 | Phoenix | Arizona | — | — |
| 251 | Tucson | Arizona | — | — |
| 160 | Covina | California | — | — |
| 257 | Hemet | California | — | — |
| 159 | Los Angeles | California | — | — |
| 201 | San Leandro | California | — | — |
| 202 | Upland | California | — | — |
| 172 | Whittier | California | — | — |
| 190 | Fort Lauderdale | Florida | — | — |
| 196 | Jupiter | Florida | — | — |
| 238 | Lake Mary | Florida | — | — |
| 232 | Miami | Florida | — | — |
| 213 | Naples | Florida | — | — |
| 214 | Ocala | Florida | — | — |
| 237 | Orange Park | Florida | — | — |
| 255 | Orlando | Florida | — | — |
| 163 | Palm Harbor | Florida | — | — |
| 166 | Plantation | Florida | — | — |
| 192 | Sarasota | Florida | — | — |
| 200 | Vero Beach | Florida | — | — |
| 226 | Coeur d'Alene | Idaho | — | — |
| 244 | Springfield | Illinois | — | — |
| 224 | South Bend | Indiana | — | — |
| 215 | Cedar Rapids | Iowa | — | — |
| 191 | Wichita | Kansas | — | — |
| 210 | Wichita | Kansas | — | — |
| 177 | Hagerstown | Maryland | — | — |
| 199 | Kalamazoo | Michigan | — | — |
| 198 | Eagan | Minnesota | — | — |
| 203 | Tupelo | Mississippi | — | — |
| 179 | St Louis | Missouri | — | — |
| 181 | Lincoln | Nebraska | — | — |
| 256 | Reno | Nevada | — | — |
| 229 | Lebanon | New Hampshire | — | — |
| 228 | Clifton | New Jersey | — | — |
| 207 | Albuquerque | New Mexico | — | — |
| 176 | Brooklyn | New York | — | — |
| 242 | Plainview | New York | — | — |
| 227 | Rochester | New York | — | — |
| 236 | Durham | North Carolina | — | — |
| 245 | Middleburg Heights | Ohio | — | — |
| 241 | Oklahoma City | Oklahoma | — | — |
| 186 | Portland | Oregon | — | — |
| 195 | Bethlehem | Pennsylvania | — | — |
| 167 | Duncansville | Pennsylvania | — | — |
| 168 | Wyomissing | Pennsylvania | — | — |
| 189 | Charleston | South Carolina | — | — |
| 205 | Columbia | South Carolina | — | — |
| 204 | Hendersonville | Tennessee | — | — |
| 217 | Allen | Texas | — | — |
| 185 | Amarillo | Texas | — | — |
| 161 | Austin | Texas | — | — |
| 178 | Corpus Christi | Texas | — | — |
| 162 | Dallas | Texas | — | — |
| 184 | Houston | Texas | — | — |
| 206 | Houston | Texas | — | — |
| 223 | Houston | Texas | — | — |
| 158 | Mesquite | Texas | — | — |
| 175 | Nassau Bay | Texas | — | — |
| 249 | Plano | Texas | — | — |
| 197 | San Antonio | Texas | — | — |
| 233 | Kennewick | Washington | — | — |
| 183 | Clarksburg | West Virginia | — | — |
| 174 | Glendale | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01521923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01521923 live on ClinicalTrials.gov.